Clinical Trial Update: Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing two inhaled formulations of formoterol fumarate delivered by Pressair DPI vs Foradil Aerolizer in patients with mild to moderate asthma;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Foradil Aerolizer (formoterol fumarate inhalation powder)
• Pressair DPI (formoterol fumarate)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2016-12-22